Research & Reviews: Journal of Reports in Cancer and Treatment

Understanding Brain Tumors: A Complex Challenge in Medical Science

Gowhar Kavishwar*

Department of Oncology, Cancer Hospital, Kolkata, India

Short Communication

Received: 27-Aug-2024, Manuscript No. RCT-24-148863; **Editor assigned:** 30-Aug-2024, PreQC No. RCT-24-148863 (PQ); **Reviewed:** 13-Sep-2024, QC No. RCT-24-148863; **Revised:** 20-Sep-2024, Manuscript No. RCT-24-148863 (R); **Published:** 27-Sep-2024, DOI: 10.4172/Rep Cancer Treat.8.3.001.

***For Correspondence:**
Gowhar Kavishwar, Department of Oncology, Cancer Hospital, Kolkata, India

E-mail: kavishwarg234@gmail.com

Citation: Kavishwar G. Understanding Brain Tumors: A Complex Challenge in Medical Science. RRJ Cancer and Treatment. 2024;08:001

ABOUT THE STUDY

Brain tumors represent one of the most intricate and challenging areas of medical science. Their complexity occurs from the delicate nature of the brain itself, the diversity of tumor types and the critical need for precise diagnosis and treatment. In this commentary, we delve into the multifaceted world of brain tumors, exploring their types, symptoms, diagnostic challenges and advancements in treatment.

Types and classification

Brain tumors are broadly classified into primary and secondary tumors. Primary tumors originate within the brain or spinal cord, while secondary tumors, also known as metastatic tumors, spread to the brain from other parts of the body. Primary tumors can be further categorized into benign or malignant, though even benign tumors can cause significant problems due to their location and growth [1].

The World Health Organization (WHO) classifies brain tumors based on their histological features and genetic mutations. Gliomas, which include astrocytomas, oligodendrogliomas and ependymomas, are the most common type of primary brain tumors [2]. These tumors arise from glial cells, which support and protect neurons. Another significant category is meningiomas, tumors that develop from the meninges, the protective membranes covering the brain and spinal cord [3].

Symptoms and diagnosis

The symptoms of brain tumors can vary widely depending on their size, location and type. Common symptoms include persistent headaches, seizures, changes in vision or speech and cognitive or personality changes.

Because these symptoms can overlap with other neurological disorders, brain tumors can be difficult to diagnose. Advanced imaging techniques, such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans, play a crucial role in identifying brain tumors [4]. MRI, in particular, provides detailed images of the brain's structure and is invaluable for detecting tumors and assessing their impact on surrounding tissues. However, imaging alone is not always sufficient for a definitive diagnosis. A biopsy, where a sample of tumor tissue is examined microscopically, is often necessary to determine the tumor's type and grade.

Treatment strategies

The treatment of brain tumors involves a multidisciplinary approach, often including surgery, radiation therapy and chemotherapy. The choice of treatment depends on the tumor's type, size, location and the patient's overall health [5].

Surgery aims to remove as much of the tumor as possible without damaging critical brain functions. The goal is to alleviate symptoms and reduce the tumor's mass, which can help other treatments be more effective. However, complete removal is not always feasible, especially if the tumor is located in a critical or inaccessible part of the brain. Radiation therapy uses high-energy rays to target and kill cancer cells. It can be particularly effective for tumors that cannot be surgically removed or for residual tumor cells left after surgery [6]. Techniques such as stereotactic radiosurgery deliver precise doses of radiation to minimize damage to surrounding healthy tissue.

Chemotherapy, the use of drugs to kill cancer cells, is another common treatment. While chemotherapy is more effective for certain types of brain tumors, it can also lead to side effects that affect the patient's quality of life. Recent advances in chemotherapy drugs and delivery methods aim to improve effectiveness and reduce side effects [7].

Emerging therapies and research

Recent years have seen significant progress in brain tumor research, providing for new and more effective treatments. A specific field that shows potential immunotherapy, which leverages the body's immune system to target and remove tumor cells. Research into cancer vaccines and immune checkpoint inhibitors is ongoing, with the aim of enhancing the body's natural ability to fight brain tumors [8,9].

Another exciting development is the use of targeted therapies, which focus on specific genetic mutations or molecular pathways involved in tumor growth. These therapies offer the potential for more personalized treatment approaches, tailored to the unique characteristics of each patient's tumor [10].

Additionally, advancements in precision medicine are enabling more accurate diagnosis and treatment planning. By analyzing the genetic and molecular profiles of tumors, clinicians can better understand their behavior and response to treatment, leading to more effective and less invasive treatment options.

CONCLUSION

Brain tumors underscore the need for ongoing investment in medical research and the development of novel therapies. While significant strides have been made, the quest for more effective treatments and ultimately a cure continues. For patients and their families, travel through a brain tumor diagnosis and treatment is often a profound and challenging experience, highlighting the importance of optimism, resilience and the relentless pursuit of scientific progress.

REFERENCES

1. Pan American Health Organization. Cancer. 2020.
2. Rosenscheg M, et al. Treatment of cancer pain: A systematic review. Am J Clin Oncol. 2023;46:450-458.
3. Birdsall SM, et al. The use of medical marijuana in cancer. Curr Oncol Rep. 2016;18:40.
4. Pantoja-Ruiz C, et al. Cannabis and pain: A scoping review. Braz J Anesthesiol. 2022;72:142-151.
5. Berrington A, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009; 169: 2071-2077.
6. Allemani C, et al. Global surveillance of trends in cancer survival 2000-2014 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391:1023-1075.
7. Mamounas EP, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol. 2005;23:16-24.
8. Goss PE, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209-219.
9. Cutsem VE, et al. ESMO consensus guidelines for the management of patients with colon and rectal cancer. Ann Oncol. 2016;27:1386-1422.
10. Hellmann MD, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol. 2020;38:1505-1517.